Results 221 to 230 of about 236,815 (335)

Trends and Outcomes Following Percutaneous Coronary Intervention in Patients With Myeloproliferative Neoplasms: Insights From National Database

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Myeloproliferative neoplasms (MPN) are associated with an increased cardiovascular risk including acute coronary syndrome. However, there is a lack of comprehensive data regarding the rate of percutaneous coronary intervention (PCI), as well as the in‐hospital characteristics and outcomes for MPN patients.
Song Peng Ang, Jia Ee Chia, Chayakrit Krittanawong, Robert N. Piana, Kwan Lee, Chadi Ayoub, JR Exequiel Pineda, David Song, Debabrata Mukherjee   +8 more
wiley   +1 more source

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia? [PDF]

Oncologist
Castaño-Díez S, Álamo JR, López-Guerra M, Gómez-Hernando M, Zugasti I, Jiménez-Vicente C, Guijarro F, López-Oreja I, Esteban D, Charry P, Torrecillas V, Mont-de Torres L, Cortés-Bullich A, Bataller Á, Guardia A, Munárriz D, Carcelero E, Riu G, Triguero A, Tovar N, Vela D, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M.   +26 more
europepmc   +1 more source

8;21 Translocation in acute myeloid leukemia an ultrastructural study [PDF]

, 1984
Guido Tricot, A. Broeckaert van Orshoven
openalex   +1 more source

Mitochondria‐Catalyzed Activation of Anticancer Prodrugs

ChemCatChem, EarlyView.
Prodrug C is a water soluble, monomeric compound accumulating in mitochondria of cancer cells, where it is activated in the reaction with mitochondrial H2O2. The activation leads to the release of camptothecin that causes cell cycle arrest in G2 phase and cancer cell death.
Michael Raucheisen, Dina Attia, Marlies Körber, Alejandra Aroca Crevillén, Andrés Hidalgo, Frank Beierlein, Petra Imhof, Andriy Mokhir   +7 more
wiley   +1 more source

Severe Aortic Stenosis and Chronic Myeloid Leukemia: Considerations for Valve Management. [PDF]

JACC CardioOncol
Cunningham R, Yoo SGK, Brescia AA, Oetjen KA, Pusic I, Mitchell JD.   +5 more
europepmc   +1 more source

Contemporary Perspectives on Chronic Renal Disorders

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting ...
Deenadhayalan Ashok, Poornima Ajay Manjrekar, Bhushan C. Shetty, Sujina S. S, Rukmini Mysore Srikantiah, Sowndarya Kollampare   +5 more
wiley   +1 more source

A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia. [PDF]

Front Immunol
Wang Y, Yang X, Liu Y, Li Y.
europepmc   +1 more source

Induction of Differentiation of Mouse Myeloid Leukemia M1 Cells by Serum of Patients with Chronic Myeloid Leukemia [PDF]

, 1988
Junko Okabe‐Kado, Yoshio Honma, Moriaki Hayashi, Motoo Hozumi, K Sampi, Masaharu Sakurai, Ken‐ichiro Hino, Nobuyoshi Tsuruoka   +7 more
openalex   +1 more source

Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan‐Degrader

ChemMedChem, EarlyView.
This study introduced DCAF11 as an E3 ligase for PROTAC‐mediated histone deacetylase (HDAC) degradation. By replacing cereblon with DCAF11 as recruited E3 ligase, a selective HDAC6 degrader (A6) was transformed into pan‐HDAC degraders. The lead compound, 1j (FF2039), potently degraded HDACs from classes I, IIa, and IIb, showing strong antiproliferative
Felix Feller, Heiko Weber, Martina Miranda, Irina Honin, Maria Hanl, Finn K. Hansen   +5 more
wiley   +1 more source

Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia. [PDF]

Cell Death Dis
Xie Y, Zeng Q, Chen Z, Song J, Wang F, Liu D, Sun X, Zhang Y, Huang Q.   +8 more
europepmc   +1 more source